Materia and Peakdale Collaborate to Commercialize Metathesis-Based Privileged Scaffolds.PASADENA, Calif. & CHAPEL-EN-LE-FRITH, England -- Materia, Inc. and Peakdale Molecular Ltd. announced today their collaboration to offer metathesis-based scaffolds for the pharmaceutical industry. Under the agreement, Peakdale has acquired non-exclusive rights to practice Materia's metathesis metathesis /me·tath·e·sis/ (me-tath´e-sis) 1. artificial transfer of a morbid process. 2. a chemical reaction in which an element or radical in one compound exchanges places with another element or radical in intellectual property portfolio for the design, development, and sale of research quantities of the scaffolds. The partners will jointly identify target compounds, while Peakdale will be primarily responsible for the compounds' development, production, and initial distribution. The collaborators will introduce two new series of privileged scaffolds by the end of 2007, with further series expected to be introduced in 2008. The initial series was selected by Dr. Ray Fisher Ray Lyle Fisher (October 4 1887 in Middlebury, Vermont -November 3 1982 in Ann Arbor, Michigan) was an American pitcher in Major League Baseball. His debut game took place on July 2, 1910. His final game took place on October 2, 1920. (Peakdale's Commercial Director) because of its usefulness in exploring novel drug like space and its suitability to synthesis via metathesis. "Peakdale has demonstrated both strong design and development capabilities as well as considerable insight into the scaffolds of interest to discovery chemists," stated Dr. Michael Giardello, Materia's Chief Executive. "We are pleased to partner with them to expand metathesis' application in the pharmaceutical industry." Dr. Fisher added, "We believe that metathesis is becoming an important tool for drug discovery. Materia is our partner of choice as it is has the broadest metathesis intellectual property position and the active support of the pioneering Nobel Prize-winning chemists." About Materia Materia was founded in 1998 to commercialize olefin metathesis Olefin metathesis or transalkylidenation (in some literature, a disproportionation) is an organic reaction which involves redistribution of olefinic (alkene) bonds.[1] catalyst technology. This market-enabling, Nobel Prize-winning, green chemical technology enables chemical compounds to be synthesized with greater efficiency, under less stringent reaction conditions, and with reduced byproducts and hazardous waste Hazardous waste Any solid, liquid, or gaseous waste materials that, if improperly managed or disposed of, may pose substantial hazards to human health and the environment. Every industrial country in the world has had problems with managing hazardous wastes. . As stated by the Royal Swedish Academy of Sciences The Royal Swedish Academy of Sciences or Kungliga Vetenskapsakademien is one of the Royal Academies of Sweden. The Academy is an independent, non-governmental scientific organization which acts to promote the sciences, primarily the natural sciences and mathematics. when awarding the 2005 Nobel Prize Nobel Prize, award given for outstanding achievement in physics, chemistry, physiology or medicine, peace, or literature. The awards were established by the will of Alfred Nobel, who left a fund to provide annual prizes in the five areas listed above. , "metathesis is an example of how important basic science has been applied for the benefit of man, society, and the environment." For more information, visit: www.materia-inc.com. About Peakdale Molecular Peakdale Molecular was founded in 1992. Today, the Company's customers include many of the worlds' top pharmaceutical companies and an increasing number of biotechnology companies Top 100 Biotechnology Companies The following is a list of the top 100 biotechnology companies ranked by revenue. The first nine companies qualify for the list of the top 50 pharmaceutical companies. . Its teams of chemists combine experience in pharmaceutical R&D and process development, medicinal chemistry, parallel synthesis, and fine chemicals to deliver unique chemistry solutions to a range of drug discovery challenges. Application of less commonly used chemistry, including high temperature/pressure reactions, proprietary heterocyclic heterocyclic /het·ero·cyc·lic/ (het?er-o-sik´lik) having a closed chain or ring formation including atoms of different elements. het·er·o·cy·clic adj. chemistry, and nucleoside nucleoside Any of a class of organic compounds, including structural subunits of nucleic acids. Each consists of a molecule of a five-carbon sugar (ribose in RNA, deoxyribose in DNA) and a nitrogen-containing base, either a purine or a pyrimidine. synthesis, enables Peakdale's chemists to generate unique compounds for drug discovery. Peakdale operates in several distinct markets providing novel screening compounds, targeted screening libraries, catalogue intermediates, custom synthesis, and contract research. Further information about the Company can be obtained at www.peakdale.co.uk. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion